In contrast with previous studies, we report a complication rate associated with peripheral line use in pregnant and postpartum women that appears similar to that in non-pregnant populations.

No abstract

Medical student performance on the standardized national subject exam correlated with clinical evaluations independent of gender. Women had higher scores on both the subject examination and the clinical performance evaluations. There was no evidence of gender bias in the students' clinical evaluation scores.

No abstract

Objective To determine if serum screen analytes identify preeclamptic patients at risk for small-for-gestational-age newborns, maternal laboratory abnormalities and preterm delivery (<37 weeks gestation). Study Design Using a retrospective cohort of 102 preeclamptic patients, associations between serum screen analytes and newborn birth-weight percentile, gestational age (GA) at delivery and maternal pre-delivery laboratory abnormalities were evaluated using correlation coefficients and local polynomial regression. Results Inhibin-A and MS-AFP were inversely correlated with newborn birth weight %ile (-0.27, p=0.006; -0.35, p=0.00004) and delivery GA (r = -0.42, p<0.0001; r = -0.26, p = 0.008) and positively correlated with pre-delivery AST (r = 0.22, p=0.03; r=0.21, p=0.04) and LDH (r=0.33, p=0.0007; r= 0.29, p=0.004). A positive correlation was noted between both second trimester β-HCG and Estriol and maternal pre-delivery creatinine (0.28, p=0.004; 0.4, p < 0.0001, respectively).100% of patients with ≥2 abnormal analytes delivered prior to 37 weeks gestation. Conclusions Preeclamptic patients with abnormal serum screen analytes are more likely to have SGA newborns, deliver preterm and have pre-delivery laboratory abnormalities.